Ku Matthew, Chong Geoff, Hawkes Eliza A
Department of Clinical Haematology and Oncology, Olivia Newton John Cancer Research Institute, Austin Hospital, Heidelberg, Australia.
Department of Clinical Haematology and Oncology, Olivia Newton John Cancer Research Institute, Austin Hospital, Heidelberg, Australia; Eastern Health, Melbourne, Australia.
Blood Rev. 2017 Jan;31(1):23-35. doi: 10.1016/j.blre.2016.08.001. Epub 2016 Aug 12.
Recent proliferation of novel targeted therapies in lymphoma has been substantial. B-cell receptor pathway inhibitors and immune checkpoint inhibitors have been a major focus, however significant advances in monoclonal antibodies (MoAbs) which directly target malignant cells have also occurred. These MoAbs continue to make significant impact in lymphoma management. Novel dosing schedules of anti-CD20 MoAb rituximab potentially optimise efficacy in specific lymphoma subgroups, as certain populations may be receiving suboptimal doses using current schedules. Next-generation anti-CD20 MoAbs may surpass rituximab in terms of efficacy. MoAbs targeting other B-cell surface antigens and antibody-drug conjugates (ADCs) have yielded promising data. Bispecific antibodies that can recruit T-lymphocytes to lymphoma cells have also shown efficacy. To further improve outcomes for patients with lymphoma using MoAbs, scrupulous trial design incorporating translational research, and synergistic drug combinations will be required. This review discusses the mechanisms of action, current data and future directions involving MoAbs.
近年来，淋巴瘤新型靶向治疗药物大量涌现。B细胞受体通路抑制剂和免疫检查点抑制剂一直是主要研究重点，然而，直接靶向恶性细胞的单克隆抗体（MoAb）也取得了重大进展。这些单克隆抗体在淋巴瘤治疗中持续发挥着重要作用。抗CD20单克隆抗体利妥昔单抗的新型给药方案可能会优化特定淋巴瘤亚组的疗效，因为某些人群按照当前方案使用的剂量可能并不理想。新一代抗CD20单克隆抗体在疗效方面可能会超越利妥昔单抗。靶向其他B细胞表面抗原的单克隆抗体和抗体药物偶联物（ADC）已产生了有前景的数据。能够将T淋巴细胞募集到淋巴瘤细胞的双特异性抗体也显示出疗效。为了使用单克隆抗体进一步改善淋巴瘤患者的治疗效果，需要精心设计纳入转化研究的试验以及协同药物组合。本综述讨论了单克隆抗体的作用机制、当前数据和未来方向。
Zotero 插件